Related Experiment Videos
Clinical use of digitalis
1Hebrew Hospital for Chronic Sick, Bronx, NY 10475.
Comprehensive Therapy
|February 1, 1992
Summary
Digitalis effectively slows heart rate in atrial fibrillation and certain tachycardias but is not recommended for heart failure with normal systolic function. It can treat heart failure with reduced ejection fraction unresponsive to other therapies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Digitalis is a cardiac glycoside with a narrow therapeutic index.
- Its use in heart failure and arrhythmias requires careful consideration.
Purpose of the Study:
- To delineate appropriate clinical applications of digitalis.
- To identify contraindications and specific patient populations for digitalis therapy.
Main Methods:
- Literature review of clinical studies and guidelines on digitalis use.
- Analysis of efficacy and safety data in various cardiovascular conditions.
Main Results:
- Digitalis is indicated for rapid ventricular rate control in atrial fibrillation/flutter (excluding preexcitation) and paroxysmal supraventricular tachycardia.
- It is not recommended for heart failure with normal LV systolic function unless tachyarrhythmia is present.
- Digoxin may benefit heart failure with abnormal LV systolic function refractory to standard treatments.
- Digitalis has a low toxic-therapeutic ratio, particularly in the elderly.
- Digoxin-specific Fab fragments are effective for severe digitalis toxicity.
Conclusions:
- Digitalis has specific indications in managing supraventricular tachyarrhythmias and certain types of heart failure.
- Careful patient selection and monitoring are crucial due to its narrow therapeutic index.
- Digoxin-specific Fab fragments offer a life-saving intervention for digitalis toxicity.